TABLE 1.

Availability of amisulpride in different countries

Country	Availability (psychiatric indication)
Europe	AMS is indicated for the treatment of acute or chronic schizophrenic disorders in the following countries:‐ Austria‐ Belgium‐ Bulgary‐ Croatia‐ Cyprus‐ Czech Republic a (dysthymia)‐ Denmark‐ Estonia‐ France‐ Germany‐ Greece‐ Iceland‐ Italy a (dysthymia)‐ Latvia‐ Lithuania‐ Luxembourg‐ Norway‐ Poland‐ Portugal a (dysthymia)‐ Romania‐ Slovakia‐ Slovenia‐ Spain‐ Switzerland‐ UK
US b	Not available
Canada	Not available
Japan	Not available
China	Available (acute or chronic schizophrenic disorders)
Russia	Available (acute or chronic schizophrenic disorders)

^a AMS is licensed for dysthymia only in some european countries (e.g. Italy, Czech Republic, Portugal) (Rittmansberger et al., 2019).

^b Approved for use in the United States in February 2020 only for treatment and prevention of Postoperative Nausea and Vomiting.

Sources: European Medicines Agency (2020), Food and Drugs Administration (2020), National Centres for Advancing Translational Sciences (2020), drugs.com (2020), Generic Drugs (2018).